Obesity — ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
Citation(s)
Endoscopic Sleeve Gastroplasty (ESG) Versus Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) Versus ESG + GLP-1RA in Patients With Obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis: A Randomized Controlled Trial